Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Colchicine for COVID-19: real-time meta analysis of 40 studies
Covid Analysis, December 2022
https://c19early.org/ometa.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hunt 68% 0.32 [0.15-0.67] death Improvement, RR [CI] Treatment Control Deftereos (RCT) 77% 0.23 [0.03-1.97] death 1/55 4/50 Deftereos (RCT) 82% 0.18 [0.02-1.50] ventilation 1/55 5/50 Deftereos (RCT) 87% 0.13 [0.01-0.97] progression 1/55 7/50 Lopes (DB RCT) 80% 0.20 [0.01-4.03] death 0/36 2/36 Lopes (DB RCT) 50% 0.50 [0.10-2.56] ICU 2/36 4/36 Lopes (DB RCT) 22% 0.78 [0.64-0.94] hosp. time 36 (n) 36 (n) Brunetti (PSM) 73% 0.27 [0.08-0.89] death 3/33 11/33 Brunetti (PSM) 73% 0.27 [0.08-0.89] no disch. 3/33 11/33 Scarsi 85% 0.15 [0.06-0.37] death 122 (n) 140 (n) Salehzadeh (RCT) 23% 0.77 [0.66-0.90] hosp. time 50 (n) 50 (n) Pinzón 35% 0.65 [0.34-1.21] death 14/145 23/156 Sandhu 42% 0.58 [0.40-0.85] death 16/34 63/78 Sandhu 53% 0.47 [0.33-0.67] ventilation 16/34 68/68 Sandhu 42% 0.58 [0.40-0.85] no disch. 16/34 63/78 Rodriguez-Nava 6% 0.94 [0.61-1.47] death 16/52 85/261 Mahale -7% 1.07 [0.59-1.96] death 11/39 25/95 Valerio Pas.. (ICU) 23% 0.77 [0.31-1.94] death 5/35 12/30 ICU patients CT​1 Valerio Pas.. (ICU) 40% 0.60 [0.38-0.95] ICU 35 (n) 30 (n) ICU patients CT​1 Tardif (DB RCT) 44% 0.56 [0.19-1.67] death 5/2,235 9/2,253 Tardif (DB RCT) 20% 0.80 [0.62-1.03] death/hosp. 104/2,235 131/2,253 Tardif (DB RCT) 47% 0.53 [0.25-1.09] ventilation 11/2,235 21/2,253 Tardif (DB RCT) 20% 0.80 [0.61-1.03] hosp. 101/2,235 128/2,253 Mareev 80% 0.20 [0.01-4.01] death 0/21 2/22 Mareev 50% 0.50 [0.24-1.04] no recov. 21 (n) 22 (n) Mareev 71% 0.29 [0.13-0.63] no recov. 21 (n) 22 (n) Mareev 67% 0.33 [0.10-1.07] no recov. 21 (n) 22 (n) Mareev 26% 0.74 [0.53-1.04] hosp. time 21 (n) 22 (n) García-Posada 57% 0.43 [0.16-0.84] death 48/99 59/110 CT​1 Manenti (PSW) 76% 0.24 [0.09-0.67] death 71 (n) 70 (n) Manenti (PSW) 44% 0.56 [0.31-1.00] no recov. 71 (n) 70 (n) Mostafaie (RCT) 83% 0.17 [0.02-1.34] death 1/60 6/60 CT​1 Mostafaie (RCT) 35% 0.65 [0.53-0.81] hosp. time 59 (n) 54 (n) CT​1 Recovery C.. (RCT) -1% 1.01 [0.93-1.10] death 1,173/5,610 1,190/5,730 Recovery C.. (RCT) -18% 1.18 [0.99-1.40] ventilation 259/3,815 228/3,962 Recovery C.. (RCT) -2% 1.02 [0.96-1.09] death/int. 1,344/5,342 1,343/5,469 Recovery C.. (RCT) -2% 1.02 [0.97-1.06] no disch. 1,709/5,610 1,698/5,730 Hueda-Zavaleta 54% 0.46 [0.23-0.91] death 10/50 109/301 Kevorkian 96% 0.04 [0.01-0.21] progression 28 (n) 40 (n) CT​1 Gaitán-Dua.. (RCT) 22% 0.78 [0.44-1.36] death 22/153 28/161 CT​1 Pascual-Fi.. (RCT) 80% 0.20 [0.01-4.03] death 0/52 2/51 Pascual-Fi.. (RCT) 80% 0.20 [0.01-4.03] ventilation 0/52 2/51 Pascual-Fi.. (RCT) 51% 0.49 [0.09-2.56] ICU 2/52 4/51 Pascual-Fi.. (RCT) 87% 0.13 [0.01-0.71] 7-point status 3/52 7/51 Pascual-Fi.. (RCT) 80% 0.20 [0.01-4.03] 7-point status 0/52 2/51 Pascual-Fi.. (RCT) -15% 1.15 [0.87-1.51] hosp. time 52 (n) 51 (n) Dorward (RCT) 70% 0.30 [0.01-7.37] death 0/156 1/120 Dorward (RCT) -30% 1.30 [0.42-3.84] death/hosp. 6/156 4/133 Dorward (RCT) 22% 0.78 [0.30-1.73] death/hosp. 6/156 119/1,145 Dorward (RCT) -6% 1.06 [0.81-1.39] no recov. 156 (n) 133 (n) Absalón-.. (DB RCT) 29% 0.71 [0.21-2.40] death 4/56 6/60 Absalón-.. (DB RCT) 17% 0.83 [0.35-1.93] progression 56 (n) 60 (n) Absalón-.. (DB RCT) -13% 1.13 [0.76-1.66] no recov. 56 (n) 60 (n) Diaz (RCT) 12% 0.88 [0.70-1.12] death 131/640 142/639 Diaz (RCT) 17% 0.83 [0.67-1.02] death/int. 160/640 184/639 Diaz (RCT) 52% 0.48 [0.18-1.27] death/int. 6/93 13/102 Diaz (RCT) 17% 0.83 [0.64-1.07] death 98/515 140/634 Diaz (RCT) 25% 0.75 [0.60-0.95] death/int. 117/515 181/634 Alsultan (RCT) 36% 0.64 [0.20-2.07] death 3/14 7/21 Karakaş 13% 0.87 [0.46-1.64] death 16/165 19/171 Karakaş 16% 0.84 [0.55-1.29] ICU 30/165 37/171 Karakaş 25% 0.75 [0.65-0.87] hosp. time 165 (n) 171 (n) Pourdowlat (RCT) 73% 0.27 [0.11-0.71] hosp. 5/102 18/100 Pourdowlat (RCT) 38% 0.62 [0.41-0.94] no recov. 89 (n) 63 (n) Pourdowlat (RCT) 22% 0.78 [0.60-1.00] no recov. 89 (n) 63 (n) Gorial (RCT) 67% 0.33 [0.04-3.14] death 1/80 3/80 Gorial (RCT) 63% 0.37 [0.21-0.67] no recov. 80 (n) 80 (n) Pimenta B.. (RCT) 79% 0.21 [0.01-4.05] death 0/14 2/16 Pimenta B.. (RCT) 85% 0.15 [0.01-2.69] no improv. 0/14 3/16 Jalal (RCT) 24% 0.76 [0.62-0.93] hosp. time 36 (n) 44 (n) Cecconi (DB RCT) 29% 0.71 [0.28-1.79] death 7/119 10/120 Cecconi (DB RCT) 50% 0.50 [0.18-1.43] ventilation 5/119 10/120 Cecconi (DB RCT) 21% 0.79 [0.38-1.67] ICU 11/119 14/120 Cecconi (DB RCT) 15% 0.85 [0.50-1.43] NIV/ICU/vent./death 21/119 25/120 Eikelboom (RCT) -8% 1.08 [0.91-1.29] death 264/1,304 249/1,307 Eikelboom (RCT) -4% 1.04 [0.90-1.21] progression 368/1,304 356/1,307 Eikelboom (RCT) 2% 0.98 [0.82-1.17] progression 246/1,304 252/1,307 Eikelboom (RCT) -9% 1.09 [0.48-2.47] death 12/1,939 11/1,942 Eikelboom (RCT) -2% 1.02 [0.72-1.43] death/hosp. 66/1,939 65/1,942 Eikelboom (RCT) -2% 1.02 [0.71-1.45] hosp. 62/1,939 61/1,942 Perricone (RCT) -36% 1.36 [0.45-4.11] death 7/77 5/75 Perricone (RCT) -7% 1.07 [0.48-2.37] progression 11/77 10/75 Perricone (RCT) -30% 1.30 [0.30-5.61] ventilation 4/77 3/75 Perricone (RCT) 76% 0.24 [0.03-2.13] ICU 1/77 4/75 Perricone (RCT) 4% 0.96 [0.79-1.17] hosp. time 77 (n) 75 (n) Rahman (DB RCT) 71% 0.29 [0.10-0.92] death 4/146 13/146 Rahman (DB RCT) 71% 0.29 [0.10-0.92] progression 4/146 13/146 Rahman (DB RCT) 61% 0.39 [0.08-2.02] death 2/146 5/146 Rahman (DB RCT) 51% 0.49 [0.09-2.68] ventilation 2/146 4/146 Rahman (DB RCT) 56% 0.44 [0.13-1.43] progression 4/146 9/146 Monserrat .. (PSM) 80% 0.20 [0.02-0.93] death n/a n/a Topless 23% 0.77 [0.56-1.07] death Oztas -406% 5.06 [0.59-43.2] hosp. 5/635 1/643 Oztas -73% 1.73 [0.96-3.11] symp. case 29/635 17/643 Oztas -24% 1.24 [0.81-1.92] cases 43/635 35/643 Avanoglu Guler 79% 0.21 [0.04-0.83] oxygen 6/66 3/7 Correa-Rodríguez -150% 2.50 [0.10-60.6] oxygen 1/163 0/81 Correa-Rodríguez -150% 2.50 [0.10-60.6] hosp. 1/163 0/81 Correa-Rodríguez 7% 0.93 [0.51-1.70] no recov. 13/24 7/12 Correa-Rodríguez 1% 0.99 [0.52-1.88] cases 24/163 12/81 Colchicine COVID-19 outcomes c19early.org/o Dec 2022 1 CT: study uses combined treatment Favors colchicine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit